LAA Occlusion Implant With Cardiac Sensing for Stroke and Arrhythmia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing blood clots in the left atrial appendage (LAA) are inconsistent and do not effectively address the risk of stroke in atrial fibrillation patients, and existing treatments like warfarin have significant side effects and compliance issues.
Innovation Solution
An implantable device with an anchoring portion, barrier element, and cardiac monitoring element that secures to the LAA to prevent clot passage and includes sensors for monitoring cardiac data, potentially providing therapy for arrhythmia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If warfarin is administered for stroke prevention, then the effectiveness of stroke prevention is improved, but serious side effects and increased risk of bleeding occur
Solution Approach 1:
The patent extracts the clot prevention function from the systemic anticoagulant approach (warfarin) and localizes it to the LAA site through an occlusion device. This eliminates the need for systemic anticoagulation and its associated bleeding risks while maintaining clot prevention effectiveness at the critical site.
Solution Approach 2:
The LAA occlusion device serves as an intermediary structure that physically blocks clots from forming and propagating from the LAA into the left atrium. This mechanical barrier replaces the chemical anticoagulant mechanism, providing stroke prevention without the harmful side effects of warfarin.
2Reliability
If LAA occlusion is performed using current FDA-approved methods (stapling or suturing), then the LAA is closed to prevent clots, but the results are inconsistent
Solution Approach 1:
The patent replaces the external mechanical closure methods (stapling/suturing from outside the LAA) with an internal occlusion device that is deployed from within the LAA. This internal approach provides more consistent and reliable occlusion by directly addressing the clot formation site without the variability of external closure techniques.
Solution Approach 2:
Instead of closing the LAA from the outside (proximal to distal), the invention inverts the approach by deploying the occlusion device from the distal end of the LAA back toward the ostium. This reverse deployment ensures complete occlusion of the entire LAA cavity, providing more consistent results than traditional methods.
3Reliability
If the LAA is blocked from the atrium to prevent thrombus entry, then stroke prevention is improved, but arrhythmia treatment is not addressed
Solution Approach 1:
The patent merges two separate functions (LAA occlusion for stroke prevention and arrhythmia monitoring/treatment) into a single integrated device. The occlusion device includes electrodes and monitoring capabilities that allow simultaneous management of both stroke risk and arrhythmia conditions in one implantable system.
Solution Approach 2:
The LAA occlusion device is designed with multi-functionality, serving both as a mechanical barrier to prevent clots and as a monitoring/treatment system for arrhythmias. This universal device addresses multiple patient needs (stroke prevention and arrhythmia management) simultaneously, improving overall patient care.
Data Source
AI summary
Atrial appendage occlusion devices and cardiac monitoring positioned within the left atrial appendage and/or left atrium. In some embodiments the devices include an anchoring portion adapted to anchor the device in place adjacent the left atrial appendage, the anchoring portion comprising distal deformable anchoring portion adapted to be deployed in the left atrial appendage and a proximal deformable anchoring portion being adapted to be deployed in the left atrium, a barrier element secured to the anchoring portion and adapted to cover the left atrial appendage when implanted, and adapted to prevent blood clots from passing through the barrier element, and a cardiac monitoring element secured to at least one of the anchoring portions, the monitoring element including one or more sensors within in the left atrial appendage and/or left atrium and adapted to monitor left atrial cardiac data.